Loading data for SCNX — first visit, this takes a few seconds.

알림

Scienture Inc. (SCNX)

NasdaqCM: SCNX · 실시간 가격 · USD

0.45

-0.01 (-2.17%)

종가 기준: Aug 18, 2026, 8:00 PM

0.45

-2.60%

프리마켓: 4:36 AM

-2.17% (1D)

데이터 없음

매수호가	0.03
시가총액	18.76M
매출 (ttm)	821.32K
순이익 (ttm)	-37.95M
베타	n/a
EPS (ttm)	-1.98
P/E (ttm)	n/a
선행 P/E	n/a
P/B (ttm)	0.28
P/S (ttm)	22.84
Earnings Date	n/a

매도호가	0.4
거래량	149,915
평균 거래량 (20일)	2,538,061
시가	0.46
전일 종가	0.46
일중 범위	0.43 - 0.46
52주 범위	0.24 - 2.60
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	2024년 7월 19일

SCNX 소개

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left vent...

[더 보기]

산업 Pharmaceutical Retailers

섹터 Healthcare

IPO 일자 Feb 6, 2014

직원 수 4

상장 거래소 NasdaqCM

티커 SCNX

웹사이트 https://scienture.com

전체 기업 정보

재무 실적

2025년 Scienture의 매출은 431.61K로, 전년 136.64K 대비 215.87% 증가했습니다. 순이익은 -41.51M로, -557.9% 감소했습니다.

재무제표

어닝 서프라이즈

Scienture가 Aug 13, 2026에 분기 실적을 발표했습니다:

매출 $56.33K 예상치 하회 $0, 및 449.08% 전년 대비 성장.

EPS -0.07 예상치 상회 0.02, 및 -Infinity% 전년 대비 감소.

뉴스

1주 전 · InvestorsHub

SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product

SCIENTURE has commercially launched REZENOPY, its 10 mg naloxone nasal spray, and fulfilled initial purchase orders to U. S.

1주 전 · Benzinga

EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US

Pharmaceutical firm Scienture Holdings, Inc. (NASDAQ:SCNX) on Wednesday officially initiated the commercial rollout of Rezenopy, a 10-milligram naloxone hydrochloride nasal spray. The company has succ...

2개월 전 · Benzinga

EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch

Scienture Holdings Inc. (NASDAQ:SCNX) said Tuesday that its opioid overdose treatment Rezenopy (naloxone HCl) Nasal Spray 10 mg has been added to the formulary of a large national health plan, broaden...

5개월 전 · Associated Press Finance

BC-Most Active Stocks

Elong Power Holding Ltd. 79,546,080 0.0559

8개월 전 · TipRanks

Scienture, BlinkRx announce strategic collaboration to expand access to Arbli

Scienture (SCNX) announced a strategic collaboration to expand national access to Arbli, the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Arbli is expected to be...

2 페이지 중 1

Scienture Inc. (SCNX)